News

4D Molecular Therapeutics, Inc.: 4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
Enrolled first patients in first 4D-150 Phase 3 clinical trial (4FRONT-1) in wet AMD, with over 50 clinical trial sites open to dateInitiation of second 4D-150 Phase 3 clinical trial (4FRONT-2) expect ...
The Manila Times16h
4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
4D-150 continues to be well tolerated during up to three years of follow-up in all patients (n=71) treated with 3E10 vg/eye dose, with the highest 4D-150-related intraocular inflammation (SUN/NEI ...
Figma2025: Websites and responsive layout via AI
The Figma design tool receives a range of new tools to generate websites and apps using AI. It also automates content ...
Unlock Stunning Power BI Dashboards with SVG and DAX
Discover how SVG and DAX can transform Power BI dashboards into stunning, interactive visuals. Learn customization tips and ...
Kytopen and Bio-Techne Collaborate on an Integrated Cellular Engineering Workflow to Expedite Cell Therapy Manufacturing
Kytopen Corp., a leader in providing continuous flow cellular engineering technologies and Bio-Techne Corporation (NASDAQ: TECH), a leading provider of innovative life science research tools today ...